Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-08154225 in Autoimmune Diseases (SLE, RA, IIM, SSc)
NCT07782450Phase 2Not yet recruiting
- Sponsor
- Pfizer
- Start
- Nov 2026
- Primary completion
- Feb 2031
01
Overview
A Phase 2 trial of PF-08154225 in systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), idiopathic inflammatory myopathies (IIM), systemic sclerosis (SSc), sponsored by Pfizer. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
PF-08154225
03
Conditions
systemic lupus erythematosus (SLE)rheumatoid arthritis (RA)idiopathic inflammatory myopathies (IIM)systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT07782450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07782450.